Our products
Ferring has developed a wide range of innovative treatments to change the lives of people and families around the world.
CARBETOCIN FERRING (carbetocin, room temperature-stable formulation)
CARBETOCIN FERRING (carbetocin, room-temperature stable formulation) is Ferring’s long-acting, oxytocin analogue that is used to prevent uterine haemorrhage due to postpartum uterine atony.
CARBETOCIN FERRING is intended for use by Health Care Professionals only and is administered via a single intravenous or intramuscular injection as soon as possible after delivery of the infant and preferably before the delivery of the placenta. CARBETOCIN FERRING is contraindicated for use in pregnancy and labour before delivery of the infant, induction or augmentation of labour, serious cardiovascular disorders, epilepsy, renal or hepatic disorders, hypersensitivity to carbetocin, oxytocin or any of the excipients according to the composition.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations.
For specific product information please consult the summary of product characteristics (SmPC) or the patient information leaflet. For advice on medical issues please consult your local medical practitioner.
To know more about Ferring’s commitment to reduce maternal and infant mortality please visit our Safe Birth page.
CHORAGON® / BREVACTID® (u-hCG)
CHORAGON (u-hCG) is a glycopeptide hormone administered by intramuscular injection and used to control the timing of ovulation.
HCG mimics the action of LH and is the drug of choice to trigger ovulation following follicular stimulation and development. It is also used in combination with MENOPUR / MENOGON to stimulate spermatogenesis in male infertility due to hypogonadism.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
GONAPEPTYL® / DECAPEPTYL® daily (triptorelin acetat)
GONAPEPTYL / DECAPEPTYL* (triptorelin acetat) is a solution for injection containing 0.1 mg/1 ml of triptorelin acetate (per prefilled syringe). It is indicated for the down regulation of the pituitary before and during controlled ovarian hyperstimulation in assisted reproduction techniques.
DECAPEPTYL in men suppresses the action of testosterone and oestrogen making it a standard therapy for diseases that depend on hormones, such as prostate cancer where it slows the development of the cancer.
(*In certain markets, the DECAPEPTYL trademark is owned by Debiopharm International S.A. and is not associated with Ferring.)
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
ENDOMETRIN® / LUTINUS® (progesterone)
LUTINUS / ENDOMETRIN (progesterone) is a vaginal tablet containing 100 mg progesterone per tablet. It is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment programme for infertile women.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject
to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
ENDOMETRIN®/ LUTINUS® (progesterone) – Status Update
5 December 2023 – Ferring Pharmaceuticals has initiated a voluntary and precautionary recall of ENDOMETRIN® / LUTINUS® (progesterone) vaginal tablet 100 mg batches in the United States, Canada, Japan, Saudi Arabia, and Turkey.
This action follows detection of Burkholderia bacteria in four unreleased batches of ENDOMETRIN / LUTINUS during final quality control conducted by the contract
manufacturing organization. The recall does not apply to the existing supply in other countries because they have not received batches within the scope of the recall.
Ferring is working with the contract manufacturing organization to determine the root cause and implement corrective measures. While deeper investigations then initially planned are ongoing, production remain suspended. The temporary drug shortage is expected to last until end of Q2 2024. The temporary drug shortage will, in varying degrees, impact approximately 20 countries worldwide.
Multiple alternative progesterone products are available from other manufacturers. Patients with questions should consult with their healthcare provider.
At this time, Ferring has no evidence suggesting that the safety or efficacy of the recalled batches has been impacted. Further, it should be emphasized that Burkholderia was not detected in any of the recalled batches.
Ferring Pharmaceuticals is committed to providing safe and effective treatments for patients. We understand the importance of ENDOMETRIN / LUTINUS to patients, and we sincerely regret any inconvenience caused by this supply disruption.
LUTREPULSE® / LUTRELEF® (gonadorelin acetate)
LUTREPULSE® / LUTRELEF® (gonadorelin acetate) is used in replacement therapy of endogenous GnRH-deficiency, for the treatment of infertility in women and men. This can induce sexual development, follicle maturation and ovulation in women whose normal secretion of GnRH (and therefore of FSH and LH) is affected. It can also be used in men to induce sperm production.
LUTREPULSE® / LUTRELEF® is administered automatically using an injection device (Pod). The Pod comes together with the Manager, a remote control used to set up the Pod and monitor its function.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
MENOPUR® / MENOGON® / REPRONEX® (HP-hMG)
MENOPUR (HP-hMG) is a highly purified human menopausal gonadotrophin containing a 1:1 ratio of FSH (follicle stimulating hormone) and LH (luteinizing hormone) activity.
MENOPUR has indications for treatment of female and male infertility in the following groups of patients*:
• Anovulatory women: MENOPUR can be used to stimulate follicle development in amenorrhoeic patients
• Women undergoing superovulation within a medically assisted fertilisation programme: MENOPUR can be used to induce multiple follicular development in patients undergoing an assisted conception technique such as in-vitro fertilisation (IVF).
• Hypogonadotrophic hypogonadism in men: MENOPUR may be given in combination with human chorionic gonadotrophin (e.g. CHORAGON®) for the stimulation of spermatogenesis.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group.
*Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
Menopur® (menotropins for injection) – Status Update
08 May 2023 – Ferring Pharmaceuticals is committed to providing safe and effective treatments for patients.
Where applicable and in accordance with feedback received from health authorities, Ferring has resumed shipments of Menopur® in the United States and other countries.
Ferring suspended shipments after the company was made aware of changes in the manufacturing process of the drug substance for Menopur.
Ferring notified national health authorities and – as a precautionary measure – suspended all shipments of Menopur* (all presentations).
Data reviewed by Ferring to date indicates that the safety and efficacy of the product remains unaltered. Ferring is not aware of any evidence indicating that the changes in the manufacturing process pose any risks to patients.
Ferring understands the importance of Menopur to our patients, physicians, and customers and sincerely regrets any inconvenience caused by the supply disruption.
For global medical enquiries contact Ferring at GlobalMedical@ferring.com. For U.S. medical enquiries call 1-888-FERRING (1-888-337-7464), or email MedQueriesUS@ferring.com.
*Menopur, Merapur, Menogon HP, Menotrophin Ferring, HMG injection, Menotropin
NORPROLAC® (quinagolide hydrochloride)
NORPROLAC (quinagolide hydrochloride) is a selective, D2 dopamine agonist that is used for the treatment of elevated levels of prolactin. The secretion of prolactin is reduced by the neurotransmitter dopamine which acts on prolactin-secreting cells in the pituitary gland. NORPROLAC mimics the action of dopamine in the pituitary to reduce prolactin levels. NORPROLAC is provided in tablet form for oral administration.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
PABAL® / DURATOCIN® / LONACTENE® / DURATOBAL® (carbetocin)
PABAL / DURATOCIN / LONACTENE / DURATOBAL (carbetocin) is Ferring’s long-acting, oxytocin analogue that is used to prevent haemorrhage following caesarean section.
Haemorrhaging from the uterus can occur following an incomplete abortion, a caesarean section or following the final stage of labour, once the placenta has been expelled, due to insufficient tone in the uterus (atony).
PABAL is administered via a single intravenous injection before or after the delivery of the placenta.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
PROPESS® / CERVIDIL® (dinoprostone)
PROPESS® / CERVIDIL®* (dinoprostone) is indicated for initiation of cervical ripening in patients at term.
PROPESS is administered through a vaginal insert contained in a polyester pouch with a withdrawal tape.
PROPESS releases dinoprostone at a constant and controlled rate. If, for any reason, treatment must be interrupted, the vaginal insert can quickly and easily be pulled out.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
REKOVELLE®
REKOVELLE® (follitropin delta) is the first recombinant follicle stimulating hormone (FSH) derived from a human cell line.
REKOVELLE® is indicated for controlled ovarian stimulation (COS) for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.
REKOVELLE® is administered using an individualised dosing regimen according to a woman’s serum anti-Müllerian hormone (AMH) level and her body weight.
AMH is a biomarker used to assess ovarian reserve and predict ovarian response to COS. AMH levels are measured using a companion diagnostic, the Elecsys® AMH Plus immunoassay from Roche.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
TRACTOCILE® (atosiban)
TRACTOCILE (atosiban) is a treatment indicated to delay imminent pre-term birth, which is the main cause of death and disability in new-born infants. The active ingredient, atosiban, is an oxytocin/vasopressin antagonist that blocks the action of oxytocin and is able to prevent uterine contractions and relax the uterus.
TRACTOCILE is administered by an intravenous infusion in three successive stages to delay imminent preterm birth.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
CORTIMENT® MMX® (budesonide)
CORTIMENT® MMX® (budesonide)* is indicated in adults for induction of remission in patients with active mild-to-moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not sufficient.
CORTIMENT® MMX® contains budesonide, a locally acting glucocorticosteroid, in a novel, patented, oral tablet formulation utilizing MMX® multimatrix colonic delivery technology that is designed to result in the controlled release and distribution of budesonide throughout the length of the colon.
(*CORTIMENT® MMX® has been developed by Cosmo Pharmaceuticals S.A. Ferring is the licensee in the EU and Asia (excluding Japan), Australia, Canada, Latin America and Africa. In the United States, where the product is available as UCERIS®, the licensee is Salix Pharmaceuticals, Inc.
CORTIMENT is a trademark of Ferring B.V. MMX is a trademark of Cosmo Pharmaceuticals S.A. UCERIS is a registered trademark of Santarus, Inc, a wholly owned subsidiary of Salix Pharmaceuticals, Inc.)
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.
GLYPRESSIN® (terlipressin)
GLYPRESSIN (terlipressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1.
GLYPRESSIN is administered to patients by the healthcare professional giving an injection directly into a vein.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.
PENTASA® (mesalazine)
PENTASA® (mesalazine) is Ferring’s product used for the treatment and long-term management of inflammatory bowel diseases (IBD) (Ulcerative colitis and Crohn’s disease).
PENTASA is prescribed to treat the mild to moderate symptoms of active IBD as well as being used widely as maintenance therapy to reduce the risk of recurrent attacks.
PENTASA is available orally as tablets and granules (sachets) within Europe and the rest of the world, excluding the USA. In the USA, Shire US, Inc. sells PENTASA under a trademark license from Ferring.
Topical formulations (suppositories and enemas) are also available for administration via the rectum, allowing a high concentration of the drug to be in contact with areas of inflammation at the lower end of the digestive tract.
Oral PENTASA has a prolonged-release formulation, helping to ensure release of active mesalazine throughout the entire length of the intestine from the duodenum to the rectum. Topical PENTASA formulations (enemas and suppositories) enable active mesalazine to remain in contact with the inflamed mucosa for several hours.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.
PICOPREP® (sodium picosulphate, magnesium oxide, citric acid)
PICOPREP® (sodium picosulphate, magnesium oxide, citric acid) is indicated to clean the bowel prior to Xray examination or endoscopy, to clean the bowel prior to surgery when judged clinically necessary.
PICOPREP® has approved dosing for children as of 1 year old and adults.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.
REBYOTA® (fecal microbiota, live — jslm)
REBYOTA® (fecal microbiota, live —jslm) is a novel first-in-class microbiome-based treatment approved by the U.S. FDA for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older, following antibiotic treatment for recurrent CDI. CDI can cause debilitating symptoms such as severe diarrhoea, fever, stomach tendeness or pain, loss of appetite and nausea. Up to 35% of CDI cases responding to initial antibiotic treatment may recur and up to 60% of these cases will experience further multiple recurrence.
This product is currently approved for use in the United States only.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
ADSTILADRIN® (nadofaragene firadenovec-vncg)
ADSTILADRIN® (nadofaragene firadenovec-vncg) is a non-replicating adenovirus vector-based gene therapy approved by the U.S. FDA for the treatment of adult patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumours.
This product is currently approved for use in the United States only.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
FIRMAGON® (degarelix)
FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly used.
Decreasing testosterone levels can cause the cancer cells to die, thus reducing the size of the tumour and delaying its growth.
To date, FIRMAGON has been approved in 74 countries.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
MINIRIN® (desmopressin)
MINIRIN® (desmopressin) is indicated for the treatment of bedwetting in children and nocturia in adults.
Both conditions are usually caused by an overproduction of urine at night, and MINIRIN acts on the kidneys to reduce this. Bedwetting can be traumatic for children, affecting their well-being and self-esteem. For adults with nocturia, waking up several times a night to urinate can lead to sleep deprivation affecting a patient’s quality of life.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
Ferring Statement on Minirin®/Octostim®/DDAVP®/Stimate® (desmopressin) Nasal Spray
Saint-Prex, Switzerland – 05 June 2024 – Minirin® (desmopressin) Nasal Spray 0.1 mg/ml room temperature stable (RTS)/ Octostim®(desmopressin) Nasal Spray 1.5 mg/ml/ DDAVP® (desmopressin acetate, 10 mcg/0.1 mL)/ Stimate® (desmopressin acetate, 1.5 mg/1 mL) Nasal Spray/ Generic Desmopressin Acetate (10 mcg/0.1mL) Nasal Spray – Recall and Production Hold Statement.
Following the detection of out-of-specification results during testing, in 2020 Ferring initiated a precautionary voluntary global recall of all batches of the following products:
- Minirin® (desmopressin) Nasal Spray 0.1 mg/ml room temperature stable (RTS) formulation
- Octostim® (desmopressin) Nasal Spray 1.5 mg/ml
Following investigation, the root cause of the out-of-specification results was identified as a tightness issue with the primary packaging materials.
To resolve this issue, new machinery was introduced in our manufacturing facility in June 2023, and a new assembly process designed. Validation batches were successfully manufactured in Q4 2023 for both products, and placed on stability. Pending successful stability results, Ferring expects to submit the variation application to the European and US regulatory authorities in Q3 and Q4 of 2024, respectively. We anticipate regulatory submissions in the rest of the world to follow in due course.
Ferring is committed to ensuring that our medicines adhere to the highest quality standards for our patients, and to working with health authorities to ensure alternatives for patients. Any patients or caregivers with concerns or questions about treatment alternatives should immediately contact their treating physician.
US and Canada
If you are based in the United States, please call our Medical Information line at 1-888-FERRING (1-888-337-7464) to discuss your question. You can also email MedQueriesUS@ferring.com. If you are based in Canada, please contact info@ferring.com with your question and share your contact telephone number so that a member of the local team can contact you.
Europe
If you are based in Europe, please contact info@ferring.com with your question and share your contact telephone number so that a member of your local team can contact you.
Asia-Pacific
If you are based in India, please contact medicaldesk.india@ferring.com and share your question and contact telephone number so that a member of the local team can contact you. If you are based in other locations in Asia-Pacific, please contact info@ferring.com with your question and share your contact telephone number so that a member of the local team can contact you.
Latin America
If you are based in Latin America, please contact info@ferring.com with your question and share your contact telephone number so that a member of the local team can contact you.
Middle East and Africa
If you are based in the Middle East or Africa, please email info@ferring.com with your question and share your contact telephone number so that a member of the local team can contact you.
NOCDURNA® (desmopressin)
NOCDURNA® (desmopressin) is indicated for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. Nocturia, the need to awaken at night to pass urine, is a complex medical condition with various contributing factors. The night-time overproduction of urine, nocturnal polyuria, is responsible for nocturia in up to 88% of cases. NOCDURNA® once-daily lyophilisate tablets are administered sublingually (without the need for water) in gender specific low doses, tailored specifically for men (50 mcg) and women (25 mcg).
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
ZOMACTON® (somatropin)
ZOMACTON® (somatropin) is a synthetic human growth hormone (hGH) produced by recombinant DNA technology.
The main use for the product is to treat Growth Hormone Deficiency (GHD) in children.
How to use ZOMACTON
Somatropin is broken down by the digestive system and therefore cannot be taken by mouth. It needs to be administered through the skin as an injection.
Cases of Growth Hormone Deficiency (GHD) should ideally be treated on a nightly basis (at bedtime) with somatropin. The dose and exact schedule of administration is based on an individual assessment of each patient, but the treatment is over several years.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.
EUFLEXXA (1% sodium hyaluronate)
Ferring’s product EUFLEXXA® (1% sodium hyaluronate) is an ultra-high purity hyaluronan, called hyaluronic acid (HA). HA is the natural substance found in the fluid that surrounds a healthy knee joint and helps cushion, lubricate, and protect the knee as it moves throughout the day.
EUFLEXXA® is injected into the knees of osteoarthritis sufferers to improve movement and reduce pain.
Please note that product information presented on this website is intended only as a brief summary for the visitor’s convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For specific product information please consult the summary of product characteristics (SPC). For advice on medical issues please consult your local medical practitioner.
